Sibutramine was also well tolerated, although it may cause dry
mouth, anorexia, and insomnia, and should be used with caution in
patients at risk for cardiovascular disease.
* Clin Ther 2003 Jan;25(1):58-80 --
Weight management and current options in pharmacotherapy: Orlistat
and sibutramine. -- Leung WY, Neil Thomas G, Chan JC, Tomlinson B.
Sibutramine increases norepinephrine and serotonin levels in
the CNS and should not be taken with many antidepressants because of
the risk of increased norepinephrine and serotonin levels. Its use
is also contraindicated in patients with cardiovascular disease.
* Am J Health Syst Pharm 2001 Jul
15;58(14):1301-8 -- Pharmacologic options for the treatment of
obesity. -* Campbell ML, Mathys ML.
Sibutramine should be used with caution in patients with a
history of hypertension and should not be used in those with
uncontrolled hypertension and concomitant cardiovascular disease.
* Ann Pharmacother 1999
Sep;33(9):968-78 -- Sibutramine : a serotonin-norepinephrine
reuptake-inhibitor for the treatment of obesity. -- Luque CA, Rey
A small increase in heart rate and blood pressure also occurs and
persists for as long as treatment is continued, which, therefore,
* Obes Rev 2000 Oct;1(2):127-39 -- An
assessment of the safety and efficacy of Sibutramine , an
anti-obesity drug with a novel mechanism of action. -- Nisoli E,
The use of Sibutramine in those under the age of 16 and those
over the age of 65 has not been tested.
* Int J Obes Relat Metab Disord 2001
Dec;25 Suppl 4:S2-7 -- When, for whom and how to use sibutramine? --
Astrup A, Toubro S.
To maximize the benefits of Sibutramine , it is important
that patients receive adjunctive diet and lifestyle therapy.
* Int J Obes Relat Metab Disord 2002
Dec;26 Suppl 4:S29-33 -- Sibutramine : its mode of action and
efficacy. -- Finer N.
Treatment with the drug decreases visceral fat, improves lipid
levels, decreases glycosylated haemoglobin and decreases uric acid
concentrations. Sibutramine is effective in achieving weight
loss in patients with type 2 diabetes but weight loss occurs more
slowly than in non-diabetic patients. The criteria for predicting
response to treatment in uncomplicated patients may not be
appropriate to those with type 2 diabetes. Furthermore, it is
important to set realistic goals for weight loss in type 2 diabetes
to avoid the risk of denying effective treatment to patients.
* Int J Obes Relat Metab Disord
2002 Dec;26 Suppl 4:S34-7 -- Metabolic benefits associated with
Sibutramine therapy. -- Krejs GJ.
Sibutramine can interact with a number of prescription and
over the counter medications. Consult with your physician before
using other drugs, herbs and supplements.
Not recommended if you are pregnant,
planning to be or breastfeeding.